This has led to FDA approval of pembrolizumab, nivolumab, and atezolizumab in the treatment of NSCLC, and approval of single-agent pembrolizumab as first-line therapy for PD-L1–positive advanced NSCLC (5). This evidence concerns the gene CD274 and non-small cell lung carcinoma.